Researchers from Abo Akademi University, Turku Center for Biotechnology discuss findings in cancer gene therapy

New investigation results, "Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus," are detailed in a study published in Journal of Gene Medicine - Gene Therapy Clinical Trial Database. "Clinical gene therapy trials using standard Ad5-based vectors have thus far demonstrated limited efficacy, most likely due to low expression levels of adenoviral receptors on tumor cells. We sought to analyze adenoviral receptor expression levels on primary head and neck squamous cell carcinoma (HNSCC) cells and to determine whether adenoviral retargeting to the CD46 receptor via the Ad5/35 system would increase therapeutic potential for HNSCC," investigators in Turku, Finland...

Want to see the full article?

• Purchase this article for only $3.00